29th July 2025 | |
9:30 | Registration Networking & Coffee |
10:30 | Opening Remarks Katsuhiro Uto, CEO, FIMECS |
Morning Session, Chair: Katsuhiro Uto | |
10:35 |
Keynote Presentation Bexobrutideg(NX-5948): Leading the Way to the First CNS-Active BTK Degrader for B-Cell Malignancies and Charting a Path to Our Next Generation of Innovative Drugs Gwenn Hansen, CSO, Nurix Therapeutics, Inc.
|
11:20 |
Targeted Degradation of TRK for Cancer Therapy and Pain Management JialiangWang, Executive VP of Operation, Cullgen, Inc.
|
11:45 |
Discovery and Clinical Development of Targeted Protein Degraders and Degrader- Antibody Conjugates (DACs) Koichi Ito, Senior Director Biology, Prelude Therapeutics
|
12:10 | Luncheon Sponsor Showcase and Coffee Break (Lunch box will be served) |
Afternoon Session 1, Chair: Ian Churcher | |
13:20 |
Development of highly active PROTACs and research on expanding PROTAC molecular modalities Hidetomo Yokoo, Chief, Division of Organic Chemistry, National Institute of Health and Science (NIHS)
|
13:45 |
Advancing Degrader Discovery and Expanding the Landscape of E3 Ligase by RaPPIDSTM platform Kanae Gamo, CSO, FIMECS, Inc.
|
14:10 |
Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID Suman Shrestha, Postdoctoral Researcher, Princess Margaret Cancer Centre
|
14:35 | Networking & Coffee Break |
Afternoon Session 2, Chair: Suman Shrestha | |
15:20 |
Protein Knockdown Mediated by Auxin-Inducible Degron (AID) Technology Masato Kanemaki, Professor, Department of Chromosome Science, National Institute of Genetics
|
15:45 |
Linker free PROTACs Hai Rao, Professor, Southern University of Science and Technology
|
16:10 |
Induction of lysosomal degradation by IAP-based PROTACs, SNIPERs Mikihiko Naito, Professor, Graduate School of Pharmaceutical Sciences, University of Tokyo
|
16:35 |
Partner’s Presentation: WuXi AppTec In vitro Platform to Facilitate Target Protein Degrader Discovery and Approaches to Optimize its ADME Properties |
17:05 | Short Break |
17:30 |
Reception Party at the Venue (Open to All Participants) |
19:00 |
Venue Closing |
30th July 2025 | |
9:00 | Registration Networking & Coffee |
Morning Session 1, Chair: Kanae Gamo | |
9:30 | A Molecular Glue Degrader of HuRto Treat Cancer and Cancer-induced Cachexia Yong Cang, CSO and Co-founder, Degron Therapeutics
|
9:55 | Oral Therapies for Immunology: Degrading IRF5, a Highly Credentialed, Historically Undrugged Transcription Factor Veronica Campbell, Senior Director, Immunology, Kymera Therapeutics
|
10:20 | Broad-Spectrum Efficacy of CEACAM6-Targeted ADC with BET Protein Degrader in Solid Cancer Models Hiroyuki Kogai, Scientist, Eisai Co., Ltd.
|
10:45 | Coffee Break |
Morning Session 2, Chair: Masato Kanemaki | |
11:05 | Bifunctional Molecules to Break Antimicrobial Resistance Emilia Taylor, PhD Researcher, The University of Oxford
|
11:30 | Development of anti-virulence therapy against bacterial infections. Minsoo Kim, Associate Professor, Kyoto University
|
11:55 | Partner’s Presentation: FUJIFILM Liposome Technology for TPD: Improved Blood Retention Expected to Lead to Increased Tumor Exposure and Reduced Administration Frequency |
12:05 | Luncheon Sponsor Showcase and Coffee Break (Lunch box will be served) |
Afternoon Session 1, Chair: Jo Hyunsun | |
13:15 | Unleashing E3 ligases for targeted protein degradation using DNA encoded libraries and Artificial intelligence (DEL-AI) Jose Santos, Vice President, NurixTherapeutics
|
13:40 | MicDrop-Cellular DEL Screen in Droplets for TPD and beyond Ken Yamada, Associate Director, Novartis Biomedical Research
|
14:05 | New approaches to PROTACs and Molecular Glues discovery combining AI, automated synthesis and innovative biology platform Yann Gaston-Mathé, CEO and Co-Founder, Iktos
|
14:30 | Coffee Break |
Afternoon Session2, Chair: Ken Yamada | |
14:50 | High-throughput proteomic screening to identify and validate novel degrader molecules and targets Henrik Daub, Founder and CSO, NEOsphereBiotechnologies
|
15:15 | Generative AI in Target Protein Degradation: What It Can Do Now and Its Future Perspective Tasuku Ishida, Lead Scientist, Elix, Inc.
|
15:40 | Partner’s Presentation: CellFreeSciences Application of MAZiQ array® Technology to TPD Drug Discovery |
15:50 | Networking & Coffee Break |
Evening Session, Chair: Gwenn Hansen | |
16:30 | Strategies for non-clinical toxicity assessment of targeted protein degraders and their challenges Masako Imaoka, Senior Director, Daiichi Sankyo Co., Ltd.
|
16:55 | Ten years of therapeutic TPD. What have we learnt and where next? Ian Churcher, Chief Executive Officer, Janus Drug Discovery Consulting Ltd
|
17:20 | Panel Discussion Advancing TPD and Molecular Glue Therapies: From Platform Innovation to Clinical Translation Panelists: Rohan Beckwith, Gwenn Hansen, Ian Churcher and Ken Yamada |
18:05 | End of Day 2 |
31st July 2025 | |
9:30 | Registration Networking & Coffee |
Morning Session 1, Chair: Jose Santos | |
9:30 | MrTAC opens enables induced lysosomal proteolysis of the cytosolic proteome Lauren Veronica Albercht, Assistant Professor, University of California Irvine
|
9:55 | Combining The Power of Protein Degraders With the Precision of Antibodies for Synergistic Potential Using Degrader-Antibody Conjugates (DACs) Sang Hyun Lee, Vice President, Orum Therapeutics
|
10:20 | Targeting ‘Undruggable’ targets: pioneering novel applications of heterobifunctional degraders Chinatsu Sakata-Sakurai, Head of Oncology Research, Astellas Pharma
|
10:45 | Networking & Coffee Break |
Morning Session 2, Chair: Jialiang Wang | |
11:15 | Brain-penetrant molecular glue degraders targeting ALK via a novel degron: A potential therapeutic approach for ALK-positive NSCLC Zheng Wang, Principal Scientist, Bristol Myers Squibb
|
11:40 | Innovative drug discovery using protein degrader Hyunsun Jo, Founder and CEO, Pin Therapeutics
|
12:05 | Expanding the Druggable Genome with Molecular Glues Rohan Beckwith, SVP Chemistry, Neomorph
|
12:30 | Closing Remark Kanae Gamo, CSO, FIMECS |